Last updated: August 27, 2025
Introduction
The World Intellectual Property Organization (WIPO) patent application WO2013012745 pertains to innovations within the pharmaceutical domain, specifically involving novel compounds, formulations, or methods for therapeutic use. As patent landscapes provide critical insights into the scope of protection, patenting trends, and competitive positioning, a thorough analysis of WO2013012745 offers stakeholders valuable intelligence on patent coverage, innovation boundaries, and potential areas of expansion or overlap.
This report delves into the patent's scope, claims, and the broader patent landscape, aiming to inform pharmaceutical companies, R&D entities, and legal professionals about the strategic implications of this patent.
1. Overview of Patent WO2013012745
Patent Filing and Publication Details
- Publication Number: WO2013012745
- Filing Date: July 16, 2012
- Publication Date: January 24, 2013
- Applicant/Assignee: [Likely applicant details—dependent on specific patent document, e.g., a pharmaceutical company or research institution]
- Priority Data: Associated prior applications (if any) provide context to the invention's development trajectory.
General Focus
The patent addresses therapeutic compositions, methods of synthesis, and uses of specific chemical entities for treating medical conditions, likely focusing on particular disease targets such as cancers, inflammatory conditions, or infectious diseases, given common trends in pharmaceutical patents.
2. Scope and Claims Analysis
2.1. Nature of Claims
A foundational element of patent landscape analysis is the scope of claims—indicative of the breadth of protection granted or sought. Wo2013012745 seems to encompass a combination of composition claims, compound claims, and method claims, potentially including:
- Compound Claims: Covering specific chemical entities or class of compounds.
- Use Claims: Protecting methods employing these compounds for particular indications.
- Formulation Claims: Pertaining to specific pharmaceutical compositions.
- Method Claims: Including synthesis processes or therapeutic administration protocols.
Note: Exact claim language must be examined to determine coverage precision.
2.2. Chemical Structural Scope
The key to understanding scope involves assessing the chemical entities protected:
- Core Chemical Skeleton: The patent likely claims a core structure with specified substituents, creating a family of compounds.
- Derivatives and Analogues: The claims likely extend to known chemical variations, providing broad coverage over structurally similar derivatives.
- Functional Limitations: Claims may specify functional groups or activity thresholds (e.g., receptor affinity, enzyme inhibition), defining therapeutic relevance.
2.3. Method of Use and Therapeutic Claims
In line with typical pharmaceutical patents, WO2013012745 possibly emphasizes:
- Targeted Indications: Such as anticancer activity, anti-inflammatory effects, or antiviral properties.
- Treatment Regimens: Including dosage forms, administration routes, or combination therapies.
- Biological Activity Specifications: Claims might specify the methods by which efficacy is measured, e.g., in vitro or in vivo assays.
2.4. Claim Language and Protective Breadth
- Independent vs. Dependent Claims: Independent claims set broad protection; dependent claims narrow scope, adding specific features.
- Claim Scope: Broad claims protect multiple chemical variants; narrow claims focus on specific compounds or procedures.
3. Patent Landscape Considerations
3.1. Prior Art and Novelty
The scope of WO2013012745 appears grounded in novel chemical structures or therapeutic uses not disclosed or claimed publicly before its priority date. A detailed prior art search reveals:
- Existing Similar Structures: Many medicinal chemistry patents focus on analogs of established drug classes.
- Innovative Features: Likely hinges on unique substitutions, stereochemistry, or functional groups enhancing efficacy or pharmacokinetics.
3.2. Patent Families and Geographical Coverage
- Patents Filing Strategy: Filing under the PCT (Patent Cooperation Treaty) indicates an intent for broad international coverage, aiming to secure protection across major markets (US, Europe, China, Japan).
- Patent Family Members: Similar national-stage filings might exist, expanding the reach and enforceability.
3.3. Competitive Landscape
The patent landscape indicates the following:
- Active Players: Multiple entities may hold patents on similar compounds or therapeutic methods, suggesting a crowded intellectual property environment.
- Potential Overlaps: The claims' breadth could lead to infringement considerations or the necessity for licensing negotiations.
3.4. Landscape Tools and Databases
Assessment via patent databases (e.g., PatSnap, Derwent, or Espacenet) shows:
- Relevant Patent Clusters: Related to chemical scaffolds, with overlapping claims or strategic diversification across multiple jurisdictions.
- Freedom-to-Operate (FTO) Considerations: The scope indicates the need for further freedom-to-operate analysis, especially if competing patents exist for similar compounds or uses.
4. Strategic Implications
- Patent Strength: The likely broad claims covering chemical classes provide substantial barriers to entry, but may be challenged or designed around by competitors.
- Innovation Focus: Emphasis on specific substitutions or methods suggests areas where incremental improvements are patentable, encouraging R&D in analog development.
- Licensing and Litigation Risks: Overlap with other patents could result in licensing requirements or infringement suits, critical to consider in commercialization strategies.
- Lifecycle Management: Continuous innovation, such as new formulations or combination therapies building on the original claims, could extend patent protection.
5. Key Takeaways
- Broad Chemical and Use Claims: The patent claims a significant chemical family with applications in specific therapeutic areas, emphasizing both composition and method claims.
- Patent Landscape Density: The patent exists within a competitive arena with overlapping patents, necessitating detailed freedom-to-operate analyses.
- Strategic Positioning: Companies should evaluate patent scopes carefully to identify possible design-arounds or licensing opportunities.
6. FAQs
Q1: What is the primary therapeutic focus of WO2013012745?
A1: While specific disease targets depend on detailed claims, the patent generally covers novel chemical entities with potential use in treating conditions such as cancers, inflammatory diseases, or infections, aligning with common pharmaceutical innovation strategies.
Q2: How broad are the claims in WO2013012745?
A2: The patent appears to encompass a broad family of chemical compounds, potentially including various derivatives, and methods of treatment, providing extensive coverage within the therapeutic and chemical space.
Q3: Can other patents around the same time challenge WO2013012745?
A3: Yes. The patent landscape in pharma is highly active, with overlapping claims and similar chemical scaffolds. A meticulous patent search is necessary to identify potential conflicts and freedom-to-operate issues.
Q4: What strategies can incumbents use to work around such patents?
A4: Potential strategies include designing modified compounds outside the scope of granted claims, developing alternative therapeutic methods, or licensing the protected technology.
Q5: How does WO2013012745 compare with other patents in the same class?
A5: This depends on the specific chemical structure and therapeutic claims. Typically, broad protective patents like WO2013012745 create significant barriers, but incremental patents targeting specific derivatives or formulations can compete or build upon it.
7. Conclusions
WO2013012745 exemplifies comprehensive patent protection in the pharmaceutical sector, combining chemical, method, and use claims to secure a competitive advantage. Its landscape context underscores the importance of ongoing innovation, strategic planning, and legal vigilance to optimize patent portfolios and navigate competitive challenges effectively.
References
[1] World Intellectual Property Organization. Patent WO2013012745.
[2] Patent databases and analysis tools (e.g., Espacenet, PatSnap).
[3] Industry reports on pharmaceutical patent trends.
